We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Quality of the NovoSeven (rFVIIa) Tratment Practice at Rigshospitalet, Copenhagen University Hospital

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Rigshospitalet, Denmark.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00192933
First Posted: September 19, 2005
Last Update Posted: October 19, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Rigshospitalet, Denmark
  Purpose
The purpose is to evaluate and improve NovoSeven treatment practice done according to our guidelines

Condition Intervention
Hemorrhage Shock Procedure: NovoSeven treatment according to guideline

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective/Prospective

Resource links provided by NLM:


Further study details as provided by Rigshospitalet, Denmark:

Study Start Date: January 2000
Estimated Study Completion Date: December 2010
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Indication for NovoSeven treatment according to our guideline

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00192933


Contacts
Contact: Pär Johansson, MD, MPA +45 3545 2030 rh08061@rh.dk
Contact: Jakob Stensballe, MD +45 3545 8269 stensballe@rh.dk

Locations
Denmark
Rigshospitalet, Copenhagen University Hospital Recruiting
Copenhagen, Denmark, DK-2100
Contact: Pär Johansson, MD, MPA    +45 3545 2030    rh08061@rh.dk   
Contact: Jakob Stensballe, MD    +45 3545 8269    stensballe@rh.dk   
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Study Chair: Pär Johansson, MD, MPA Blood Bank, Rigshospitalet, Copenhagen University Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00192933     History of Changes
Other Study ID Numbers: 2004-41-3996
First Submitted: September 13, 2005
First Posted: September 19, 2005
Last Update Posted: October 19, 2006
Last Verified: September 2005

Additional relevant MeSH terms:
Hemorrhage
Pathologic Processes